EGEstelle Guerdoux

Estelle Guerdoux

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Estelle Guerdoux has a total of 204 co-authors. Here are the top co-authors by number of shared publications:

  • Grégory Ninot

    Desbrest Institute of Epidemiology and Public Health, UMR 1318, INSERM, University of Montpellier, Montpellier, France

    8 shared publications
  • Amélie Darlix

    Department of Medical Oncology, Institut Régional du Cancer de Montpellier, University of Montpellier , Montpellier

    5 shared publications
  • Denis Brouillet

    Laboratory Epsylon EA 4556, University of Montpellier and University Paul Valéry , Montpellier , France

    5 shared publications
  • Pierre Senesse

    Department of Clinical Nutrition and Gastroenterology, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France

    5 shared publications
  • Raphaël Trouillet

    Laboratory Epsylon EA 4556, University Paul Valéry, Montpellier, France

    5 shared publications
  • Sophie Martin

    Laboratory Epsylon EA 4556, University of Montpellier and University Paul Valéry , Montpellier , France

    5 shared publications

Latest Publications

  • Open Access

    Impact of remote management using patient-reported outcomes on pain and anxiety after breast biopsy: the BIO-PSY randomized controlled trial

    by Estelle Guerdoux, Louise Coutant, Anas Al Herk, Laetitia Meignant, Guillaume Laffargue, Fanny Salasc, Jade Pibre, Stéphanie Blasco, Nolwenn Bignon, Muriel Thomaso, et al.

    Although breast biopsy is a routine procedure, it often triggers significant pain and anxiety. Pre-procedural distress has been associated with increased pain and discomfort, and persistent post-biopsy distress may affect psychological and treatment-related outcomes. However, post-biopsy care still lacks standardized follow-up. This study evaluated whether remote monitoring using patient-reported outcomes (PROs) triggering targeted interventions could improve pain and anxiety management after breast biopsy. BIO-PSY was a French, monocentric, open-labelled, randomized controlled trial. Patients aged ≥ 18 years undergoing breast biopsy were randomized (1:1:1) to daily phone-based PROs (phone contact with a psycho-oncologist for 3 days), e-PROs (electronic interface for 3 days), or standard care. Alerts generated based on PROs thresholds prompted tailored interventions. The primary endpoint was pain on day 4 (0-10 numerical rating scale, phone-assessed). Secondary outcomes included pain at day 10; anxiety and perceived aesthetic impact (days 4 and 10); insomnia (Insomnia Severity Index) at day 10; and strategies for symptoms management. Among 193 patients, pain was negligible (median = 0), stable, and not statistically different between arms at day 4 and 10 (p > 0.05). The proportion of patients with clinically significant anxiety was lower in the experimental arms than in the control arm at day 4 (p < 0.001) and was lower at day 10 only in the phone-based PRO arm (adjusted p = 0.008). Pain after breast biopsy was well controlled across all arms. Remote monitoring using PROs may reduce anxiety, especially with human intervention, supporting its integration into routine post-biopsy care. NCT04456920 (registered on June 23, 2020).

  • Open Access

    Screening for reduced food intake in 2 minutes: validation of the ingesta verbal analogue scale in medical geriatric oncology

    by Pierre Senesse, Julie Deffrennes, Nicolas Flori, Chloé Janiszewski, Laure Francioni, Simon Thezenas, Estelle Guerdoux

    Background/Objectives Reduced food intake is a key aetiological factor of malnutrition. The study purpose was to validate the ingesta Verbal Analogue Scale (ingesta-VAS), a promising tool for rapid food intake assessment, in older adults with cancer in whom malnutrition is frequent and affects treatment outcomes and survival. Subjects/Methods This prospective study focused on ≥70-year-old patients with a diet history undergoing their first oncological treatment at a French cancer centre. Exclusion criteria included surgery, oral intake cessation, or artificial nutrition use. Dietitians evaluated nutritional status, daily energy intake, and used the ingesta-VAS and Mini-Nutritional Assessment-Short Form (MNA-SF). The ingesta-VAS validity, sensitivity, specificity, and prognostic impact were assessed using daily food intake as primary criterion, then <25 kcal/kg/day as reference standard for inadequate energy intake. The Area Under the Curve was used to select the cut-off. Overall survival was assessed with the Kaplan-Meier analysis. Results The analysis involved 441 participants. The correlation between ingesta-VAS scores and energy intake was strong (\(\rho\) = 0.71), and moderate with the MNA-SF scores (\(\rho\) = 0.55, p < .001). Its sensitivity and specificity for detecting inadequate energy intake was 79.0% and 72.6%, respectively. Combined with performance status and body mass index, ingesta-VAS significantly predicted the inadequate energy intake (odds ratio: 10.2, p < 0.001). Difference in overall survival groups was significant with the cut-off of ≤7 [HR = 1.60 (95% CI: 1.29–1.98), p < 0.001]. Conclusions The ingesta-VAS exhibits reliable metrological properties and may serve as an early, non-invasive, and simple tool to screen reduced food intake in older adults with cancer for detecting the risk of malnutrition.


  • Open Access

    Impact of androgen receptor pathway inhibitors on cognitive function in elderly patients treated for metastatic prostate cancer

    by Antoine Boué, Giulia Baciarello, Emmanuel Meyer, François Christy, Nedjla Allouache, Raffaele Ratta, Philippe Beuzeboc, Pierre-Emmanuel Brachet, Estelle Guerdoux, Amelie Darlix, et al.

    Androgen receptor pathway inhibitors (ARPI) are commonly used in addition to androgen deprivation therapy (ADT) for metastatic prostate cancer (mPC). However, there is limited data on their cognitive impact in elderly patients. This prospective multicenter trial recruited castration-resistant mPC patients aged ≥70 receiving ADT+ARPI, patients receiving ADT alone, and healthy controls (HC). Cognition was assessed with a self-report questionnaire (subjective cognition) and cognitive tests addressing six domains: processing speed/attention, working memory, verbal memory, visual memory, visuospatial abilities, and executive functions (objective cognition). At baseline (before starting ARPI for ADT+ARPI patients), objective cognitive impairment concerned 36 (51%), 5 (26%) and 3 (10%) ADT+ARPI patients, ADT patients and HC, respectively. After 3 and 6 months of follow-up, adjusted scores showed poorer subjective cognition in ADT+ARPI patients than in ADT patients (p≤0.033). ADT+ARPI patients also had lower objective performance in processing speed/attention domain at all visits (p≤0.010). Although limited by small sample sizes, our study shows for the first time that ARPI+ADT can increase the risk of impacting objective and subjective cognition in elderly mPC patients, compared to ADT alone.

  • Open Access

    Accepting to Participate in an Early‐Phase Clinical Trial in Oncology: A Qualitative Study on the Patients' Experiences, Understanding, and Inner Motivations

    by Estelle Guerdoux, Anne Stoebner, Louise Coutant, Marion Zamith‐Chavant, Sylvie Dolbeault, Jessica Martinez, Marta Jarlier, Diego Tosi

    Background: The clinical trial landscape in oncology has evolved, with shifting endpoints and increased emphasis on early‐phase clinical trials (EPCTs) across European centers. Aims: This study aimed to update knowledge on the experiences of patients enrolling in EPCTs, focusing on the individual/contextual factors influencing decision‐making, and how to improve ethical and psycho‐oncological support. Methods: This qualitative single‐center study was part of a broader multicenter project. Twenty‐five patients with locally advanced or metastatic solid cancer, for whom standard therapies had failed, were interviewed face‐to‐face, at a French EPCT center. A reflexive thematic analysis of the transcripts was conducted, following Braun and Clarke's six‐step approach. Results: Four overarching themes emerged: “Experiencing the EPCT proposal”, “Accepting the EPCT”, “Ambivalent feelings” and “Coping strategies”, and several subthemes. Decisions were often made quickly in crisis situations and perceived as the only option. While patients reported receiving adequate information, their understanding of the trial's aims varied. Emotional distress and time pressure likely hindered full comprehension. Patients relied on trust in clinicians and reframed trial participation as a constructive goal, drawing on coping strategies to manage uncertainty and restore a sense of coherence. Conclusions: Patients were neither delusional nor misinformed, but their decisions were shaped by complex emotional and relational dynamics. The perception of being well informed does not ensure true understanding, especially in high‐stress contexts. Ambivalent emotions, tensions between expectations and hopes, and constrained choices should be considered when tailoring supportive care. Evidence‐based strategies are needed to enhance communication and shared decision‐making in EPCT settings.


  • Open Access

    Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocol

    by Estelle Guerdoux, Louise Coutant, Sophie Gourgou, Caroline Mollevi, Marie-Sophie Duc, Fanny Salasc, Hugues Duffau, Amélie Darlix

    Lower-grade gliomas (LrGGs) are rare tumors that mainly concern young adults, with an overall survival ranging from 5 to 20 years and without any curative treatment to date. LrGGs are frequently associated with psychological disorders and neurocognitive impairments, including memory and dysexecutive syndrome, that can negatively affect professional, familial and social functioning, ultimately reducing the patients' health-related quality of life (HRQoL). Maintaining an acceptable HRQoL is a key objective because survival outcomes tend to be better in patients with fewer psychopathological comorbidities and better HRQoL. Neuropsychological rehabilitation and cognitive behavioral therapy (CBT) have shown promising results in patients with neurological conditions, mental health disorders, and cancer. However, they are not routinely used in patients with LrGG, and onco-neuro-psychologists (i.e., neuro-psychologists trained in oncology) with expertise in neurocognition and CBT are lacking. The aim of this study protocol is to evaluate the efficacy of the remote FREEDOME program, which integrates CBT and a digital neurocognitive tool, in patients with LrGG who experience cognitive complaints post-therapeutic phase. This ongoing, prospective, open-label, multicenter, randomized trial (1:2) should include 187 patients with LrGG considered “stable” (12 months after surgery, 6 months after chemotherapy or radiotherapy) and who are not planned to receive any cancer treatment in the first 4 months after enrollment. The primary objective is to assess the FREEDOME program effects on perceived cognitive impairment at month 4 post-inclusion. Secondary objectives include patient adherence to the intervention, and effects on the subjective and objective neurocognitive functioning, HRQoL (including sleep, fatigue and return-to-work) and psychopathological symptoms over time. The study will also explore the intervention effects on the patient memory and irritability, as perceived by family caregivers. This study may represent an important step in the implementation of evidence-based neuropsychological interventions tailored to the specific needs of patients with LrGG.Clinical trial registration: ClinicalTrials.gov: NCT06468176; ID-RCB: 2023-A02376-39.


  • Open Access

    Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

    by Florien W Boele, Sé M Frances, Amélie Darlix, Francois Ducray, Stéphanie Cartalat, Estelle Guerdoux, Emeline Tabouret, Michael C Burger, Isabelle Rydén, Annika Malmstrom, et al.

    Background: Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma. Methods: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor location; treatments delivered; time since treatment; current medication) were explored with regression analyses. Results: In total, 237 patients M = 9.9 years postdiagnosis (SD = 4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (posthoc analyses for cumulative radiotherapy dose: not significant). Conclusions: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning. Trial registration: NCT04708548


  • Role and perception of healthcare professionals in referring cancer patients to online cognitive behavioral therapy for insomnia

    by Louise Zanni, Jonathan Journiac, Josée Savard, Estelle Guerdoux, Guilhem Paillard-Brunet, Léonor Fasse, Jean-Bernard Le Provost, Cécile Charles, Sarah Dauchy, Diane Boinon

    Insomnia represents a major issue in oncology, which can be successfully treated by online Cognitive-Behavioural Therapy for Insomnia, such as the Insomnet program. However, promoting its successful implementation in routine care requires healthcare providers' involvement. This study aimed to explore healthcare professionals' perceptions of this online program. This qualitative study was a part of the French Sleep-4-All-2.0 multicentric study. It explored, through two focus groups including 19 healthcare professionals of three cancer centers, their perceptions regarding their role in patient referral, and the perceived barriers and facilitators in accessing this type of intervention. The content of the focus groups was subjected to a descriptive thematic analysis. Four major themes were identified: (1) ambivalent representations of online tools (including patients convinced by remote intervention, evolution of representations in relation to the health context, adapted to sleep disorders, professionals' preconceptions of online tools), (2) barriers to implementation (including few perceived barriers, forgetting patients' particularities, professionals' lack of knowledge, a possible threat to the patient-caregiver relationship, financial cost), (3) levers for implementation (including real benefits for patients, professionals who feel confident, preserved patient-caregiver relationship, institutional innovations to remedy dysfunctions), and (4) professional involvement in implementation (what they need, what to avoid, what they already do, what they see themselves doing). Online (healthcare) services were reported to help increase access to healthcare, but that should not replace the relationship between patients and healthcare professionals. All professionals must be informed and trained to refer patients to these programs.


  • Open Access

    Integrated early palliative care for patients with newly diagnosed glioblastoma: The GLIOSUPPORT feasibility study

    by Michel Fabbro, Muriel Thomaso, Amélie Darlix, Virginie Perotin, Caroline Gallay, Marie Charissoux, Anne-Chantal Granier, Nabila Bouazza, Patrice Champoiral, Louise Coutant, et al.

    Background: Early palliative care improves the quality of life (QoL) and survival in patients with cancer; however, its effects in patients with glioblastoma remain unclear. The GLIOSUPPORT study assessed the feasibility (adherence; primary objective) of an early palliative care program integrated into the standard glioblastoma care pathway. Secondary objectives included the description of the patients’ characteristics, QoL, and neuropsychological changes over time, end-of-life decisions, end-of-life treatments, and family carers’ perceptions/experiences. Methods: This interventional, prospective, longitudinal, feasibility study was conducted in a French comprehensive cancer center. Thirty-five patients with newly diagnosed glioblastoma were required to reach an adherence rate of 60%. Adherence was defined as going to 3 palliative care visits scheduled every 12 weeks. Baseline characteristics were compared in patients who did and did not adhere to the palliative care program. Minimal clinically important differences and cut-offs were used to quantify QoL changes. Results: The adherence rate was 60% (95% CI [42.1%-76.1%]), indicating that the program was feasible. Visual disturbances, communication/initiation deficits, and anxiety were more frequent in the group that did not adhere to the program. Emotional and social functioning, pain, appetite loss, constipation, and headache increased over time (clinically significant differences), whereas neuropsychological disturbances did not change. Half of the participants identified a family proxy and 8.6% wrote advance directives. One month before death, 28.6% of patients were receiving cancer treatment. Conclusions: Integrating early palliative care in glioblastoma management is feasible. The potential benefits on QoL, mood, and survival must now be evaluated in a larger randomized controlled trial.


  • Open Access

    Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: A feasibility study

    by Amélie Darlix, Maëva Monnier, Florence Castan, Louise Coutant, Michel Fabbro, Ève Denis-Chammas, Mathilde Carrière, Nicolas Menjot-De-Champfleur, Valérie Rigau, Hugues Duffau, et al.

    Background: The treatment timing and choice after neurosurgical resection in patients with newly diagnosed diffuse low-grade glioma (DLGG) remain controversial. Indeed, the effect of such treatments must be balanced with the possible side effects. This study evaluated the feasibility of longitudinal exhaustive quality of life (QoL) and neuropsychological assessments in patients with DLGG receiving first-line temozolomide. Methods: QoL, neurocognition, and psychological disorders were assessed prospectively until disease progression, using testing, clinician-reported, and self-reported questionnaires. The primary endpoint was the participation and adherence to this complete assessment at Baseline (before temozolomide initiation), months 6 and 12 of treatment, and month 6 post-treatment. The QoL and neuropsychological changes over time also were described. Results: Twenty-six of the twenty-nine eligible patients were enrolled (participation rate: 89.7%, 95% CI: 72.6–97.8). The adherence rate was 95.7% (95% CI: 78.1–99.9; n = 23 because 3 patients progressed in the first 12 months of treatment). Up to month 6 post-treatment, QoL and fatigue remained stable (EORTC QLQC30 and BN20, MFI-20); some specific symptoms were transitory. Both subjective (FACT-Cog) and objective (Z-scores of neurocognitive tests) neurocognitive outcomes remained stable or tended to improve. The percentage of patients with severe depression (BDI-II), anxiety (STAI-Y), or anger (STAXI-II) was stable over time. Conclusions: This prospective study demonstrated the feasibility of an exhaustive and longitudinal evaluation of QoL, neurocognition, and psychological disorders, with high acceptability by patients with DLGG undergoing chemotherapy. First-line temozolomide seems to have limited short-term effects on QoL and neurocognition. These findings must be confirmed in the long term and in a larger cohort.